Document resource
The new UK-US pharmaceutical deal marks a major shift in the UK’s approach to evaluating, pricing, and adopting new medicines.1 Faster access to innovative treatments for conditions such as cancer will be welcomed by patients, clinicians, and researchers. Increased spending on drugs may also enhance the UK’s attractiveness for clinical research and stimulate further investment from the life sciences industry.